The potential of proteomics in understanding neurodegeneration

International Review of Neurobiology

Volumn 121, Issue , 2015, Pages 25-58

  Pal, Ramavati ^a   Larsen, Jan Petter ^b   Moller, Simon Geir ^a,b  

^a ST JOHN'S UNIVERSITY   (United States)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BODY FLUID; CAPILLARY ELECTROPHORESIS; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOMICS; HUMAN; HUNTINGTON CHOREA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NERVE CELL NECROSIS; NERVE DEGENERATION; NON INVASIVE MEASUREMENT; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEOMICS; QUANTITATIVE ANALYSIS; RELIABILITY; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION; TWO DIMENSIONAL ELECTROPHORESIS; ANIMAL; ANIMAL DISEASE; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROCEDURES;

ANIMAL DISEASES; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS;

EID: 84973420399     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2015.05.002     Document Type: Chapter

References (175)

1. Acquadro, E., Caron, I., Tortarolo, M., Bucci, E. M., Bendotti, C., & Corpillo, D. (2014). Human SOD1-G93A specific distribution evidenced in murine brain of a transgenic model for amyotrophic lateral sclerosis by MALDI imaging mass spectrometry. Journal of Proteome Research, 13, 1800-1809.
2. Aggarwal, K., Choe, L. H., & Lee, K. H. (2006). Shotgun proteomics using the iTRAQ isobaric tags. Briefings in Functional Genomics & Proteomics, 5, 112-120.
3. Aksenov, M. Y., Aksenova, M. V., Carney, J. M., & Butterfield, D. A. (1997). Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Radical Research, 27, 267-281.
4. Alberio, T., Bossi, A. M., Milli, A., Parma, E., Gariboldi, M. B., Tosi, G., et al. (2010). Proteomic analysis of dopamine and alpha-synuclein interplay in a cellular model of Parkinson's disease pathogenesis. The FEBS Journal, 277, 4909-4919.
5. Alberio, T., Pippione, A. C., Comi, C., Olgiati, S., Cecconi, D., Zibetti, M., et al. (2012). Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease. IUBMB Life, 64, 846-852.
6. Albertini, V., Benussi, L., Paterlini, A., Glionna, M., Prestia, A., Bocchio-Chiavetto, L., et al. (2012). Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. Electrophoresis, 33, 3738-3744.
7. Albrethsen, J. (2007). Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clinical Chemistry, 53, 852-858.
8. Al-Taher, F., Banaszewski, K., Jackson, L., Zweigenbaum, J., Ryu, D., & Cappozzo, J. (2013). Rapid method for the determination of multiple mycotoxins in wines and beers by LC-MS/MS using a stable isotope dilution assay. Journal of Agricultural and Food Chemistry, 61, 2378-2384.
9. Anderson, N. L., & Anderson, N. G. (1998). Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis, 19, 1853-1861.
10. Bantscheff, M., Lemeer, S., Savitski, M. M., & Kuster, B. (2012). Quantitative mass spectrometry in proteomics: Critical review update from 2007 to the present. Analytical and Bioanalytical Chemistry, 404, 939-965.
11. Battistini, S., Giannini, F., Greco, G., Bibbo, G., Ferrera, L., Marini, V., et al. (2005). SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. Journal of Neurology, 252, 782-788.
12. Bazan, N. G., & Lukiw, W. J. (2002). Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. The Journal of Biological Chemistry, 277, 30359-30367.
13. Berciano, J., Infante, J., Mateo, I., & Combarros, O. (2002). Hereditary ataxias and paraplegias: A clinicogenetic review. Neurología, 17, 40-51.
14. Beretta, L. (2007). Proteomics from the clinical perspective: Many hopes and much debate. Nature Methods, 4, 785-786.
15. Bergemalm, D., Forsberg, K., Jonsson, P. A., Graffmo, K. S., Brannstrom, T., Andersen, P. M., et al. (2009). Changes in the spinal cord proteome of an amyotrophic lateral sclerosis murine model determined by differential in-gel electrophoresis. Molecular & Cellular Proteomics, 8, 1306-1317.
16. Bonifati, V. (2010). Shaking the genome: New studies reveal genetic risk for Parkinson's disease. Lancet Neurology, 9, 136-138.
17. Bonifati, V., Oostra, B. A., & Heutink, P. (2004). Unraveling the pathogenesis of Parkinson's disease-The contribution of monogenic forms. Cellular and Molecular Life Sciences, 61, 1729-1750.
18. Boysen, R. I., & Hearn, M. T. (2001). HPLC of peptides and proteins. Current Protocols in Protein Science, 8(7), 1-40 (chapter 8)
19. Brettschneider, J., Lehmensiek, V., Mogel, H., Pfeifle, M., Dorst, J., Hendrich, C., et al. (2010). Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neuroscience Letters, 468, 23-27.
20. Burke, R. E. (2007). Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacology & Therapeutics, 114, 261-277.
21. Butterfield, D. A. (2004). Proteomics: A new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research, 1000, 1-7.
22. Butterfield, D. A., & Dalle-Donne, I. (2012). Redox proteomics. Antioxidants & Redox Signaling, 17, 1487-1489.
23. Cafe-Mendes, C. C., Ferro, E. S., Britto, L. R., & Martins-de-Souza, D. (2014). Using mass spectrometry-based peptidomics to understand the brain and disorders such as Parkinson's disease and schizophrenia. Current Topics in Medicinal Chemistry, 14, 369-381.
24. Campello, L., Esteve-Rudd, J., Bru-Martinez, R., Herrero, M. T., Fernandez-Villalba, E., Cuenca, N., et al. (2013). Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeys. PLoS One, 8, e74439.
25. Cao, Z., & Robinson, R. A. (2014). Proteome characterization of splenocytes from an Abetapp/ps-1 Alzheimer's disease model. Proteomics, 14, 291-297.
26. Carballo-Carbajal, I., Weber-Endress, S., Rovelli, G., Chan, D., Wolozin, B., Klein, C. L., et al. (2010). Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cellular Signalling, 22, 821-827.
27. Chang, S. H., Jung, I. S., Han, G. Y., Kim, N. H., Kim, H. J., & Kim, C. W. (2013). Proteomic profiling of brain cortex tissues in a Tau transgenic mouse model of Alzheimer's disease. Biochemical and Biophysical Research Communications, 430, 670-675.
28. Chiang, M. C., Juo, C. G., Chang, H. H., Chen, H. M., Yi, E. C., & Chern, Y. (2007). Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach. Molecular & Cellular Proteomics, 6, 781-797.
29. Chou, J. L., Shenoy, D. V., Thomas, N., Choudhary, P. K., Laferla, F. M., Goodman, S. R., et al. (2011). Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. Journal of Proteomics, 74, 466-479.
30. Cocciolo, A., Di Domenico, F., Coccia, R., Fiorini, A., Cai, J., Pierce, W. M., et al. (2012). Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radical Biology & Medicine, 53, 1868-1876.
31. Constantinescu, R., Andreasson, U., Li, S., Podust, V. N., Mattsson, N., Anckarsater, R., et al. (2010). Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism & Related Disorders, 16, 545-549.
32. Coppede, F., Mancuso, M., Siciliano, G., Migliore, L., & Murri, L. (2006). Genes and the environment in neurodegeneration. Bioscience Reports, 26, 341-367.
33. Cornett, D. S., Reyzer, M. L., Chaurand, P., & Caprioli, R. M. (2007). MALDI imaging mass spectrometry: Molecular snapshots of biochemical systems. Nature Methods, 4, 828-833.
34. Culver, B. P., Savas, J. N., Park, S. K., Choi, J. H., Zheng, S., Zeitlin, S. O., et al. (2012). Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. The Journal of Biological Chemistry, 287, 21599-21614.
35. Cuny, G. D. (2009). Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Current Pharmaceutical Design, 15, 3919-3939.
36. Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Bjorkqvist, M., Petersen, A., et al. (2007). Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research, 6, 2833-2840.
37. D'Ambrosio, C., Arena, S., Fulcoli, G., Scheinfeld, M. H., Zhou, D., D'Adamio, L., et al. (2006). Hyperphosphorylation of JNK-interacting protein 1, a protein associated with Alzheimer disease. Molecular & Cellular Proteomics, 5, 97-113.
38. David, C. (2006). The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 443, 780-786.
39. Deschepper, M., Hoogendoorn, B., Brooks, S., Dunnett, S. B., & Jones, L. (2012). Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes. Brain Research Bulletin, 88, 210-222.
40. Di Domenico, F., Sultana, R., Barone, E., Perluigi, M., Cini, C., Mancuso, C., et al. (2011). Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. Journal of Proteomics, 74, 1091-1103.
41. Dumitriu, A., Pacheco, C. D., Wilk, J. B., Strathearn, K. E., Latourelle, J. C., Goldwurm, S., et al. (2011). Cyclin-G-associated kinase modifies alpha-synuclein expression levels and toxicity in Parkinson's disease: Results from the GenePD study. Human Molecular Genetics, 20, 1478-1487.
42. Eng, J. K., McCormack, A. L., & Yates, J. R. (1994). An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. Journal of the American Society for Mass Spectrometry, 5, 976-989.
43. Farooqui, A. A., Yang, H. C., Rosenberger, T. A., & Horrocks, L. A. (1997). Phospholipase A2 and its role in brain tissue. Journal of Neurochemistry, 69, 889-901.
44. Fasano, M., & Lopiano, L. (2008). Alpha-synuclein and Parkinson's disease: A proteomic view. Expert Review of Proteomics, 5, 239-248.
45. Fenyo, D., & Beavis, R. C. (2003). A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. Analytical Chemistry, 75, 768-774.
46. Fiehn, O. (2001). Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comparative and Functional Genomics, 2, 155-168.
47. Fountoulakis, M., & Kossida, S. (2006). Proteomics-driven progress in neurodegeneration research. Electrophoresis, 27, 1556-1573.
48. Fujioka, S., & Wszolek, Z. K. (2012). Update on genetics of parkinsonism. Neuro- Degenerative Diseases, 10, 257-260.
49. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., et al. (2002). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 4, 160-164.
50. Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology, 51, 296-301.
51. Gasser, T. (2005). Genetics of Parkinson's disease. Current Opinion in Neurology, 18, 363-369.
52. Ghezzi, P., & Bonetto, V. (2003). Redox proteomics: Identification of oxidatively modified proteins. Proteomics, 3, 1145-1153.
53. Giasson, B. I., Duda, J. E., Murray, I. V., Chen, Q., Souza, J. M., Hurtig, H. I., et al. (2000). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
54. Gloeckner, C. J., Boldt, K., von Zweydorf, F., Helm, S., Wiesent, L., Sarioglu, H., et al. (2010). Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. Journal of Proteome Research, 9, 1738-1745.
55. Golbe, L. I. (2003). Alpha-synuclein and Parkinson's disease. Advances in Neurology, 91, 165-174.
56. Gorg, A., Weiss, W., & Dunn, M. J. (2004). Current two-dimensional electrophoresis technology for proteomics. Proteomics, 4, 3665-3685.
57. Guerrera, I. C., & Kleiner, O. (2005). Application of mass spectrometry in proteomics. Bioscience Reports, 25, 71-93.
58. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology, 17, 994-999.
59. Hanash, S. (2001). 2-D or not 2-D-Is there a future for 2-D gels in proteomics? Insights from the York proteomics meeting. Proteomics, 5, 635-637.
60. Hanash, S. (2003). Disease proteomics. Nature, 422, 226-232.
61. Hands, S. L., & Wyttenbach, A. (2010). Neurotoxic protein oligomerisation associated with polyglutamine diseases. Acta Neuropathologica, 120, 419-437.
62. Haqqani, A. S., Kelly, J. F., & Stanimirovic, D. B. (2008). Quantitative protein profiling by mass spectrometry using label-free proteomics. Methods in Molecular Biology, 439, 241-256.
63. Hardy, J., Cai, H., Cookson, M. R., Gwinn-Hardy, K., & Singleton, A. (2006). Genetics of Parkinson's disease and parkinsonism. Annals of Neurology, 60, 389-398.
64. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297, 353-356.
65. Henkel, A., Müller, K., Lewczuk, P., Müller, T., Marcus, K., Kornhuber, J., et al. (2012). Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: A pilot study. Journal of Neural Transmission, 119, 779-788.
66. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., et al. (1995). Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. Journal of Neurochemistry, 65, 2146-2156.
67. Ho, C. S., Lam, C. W., Chan, M. H., Cheung, R. C., Law, L. K., Lit, L. C., et al. (2003). Electrospray ionisation mass spectrometry: Principles and clinical applications. Clinical Biochemist Reviews, 24, 3-12.
68. Holmes, C. (2002). Genotype and phenotype in Alzheimer's disease. The British Journal of Psychiatry, 180, 131-134.
69. Hong, I., Kang, T., Yoo, Y., Park, R., Lee, J., Lee, S., et al. (2013). Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology. Journal of Alzheimer's Disease, 36, 321-334.
70. Hsu, C. H., Chan, D., & Wolozin, B. (2010). LRRK2 and the stress response: Interaction with MKKs and JNK-interacting proteins. Neuro-Degenerative Diseases, 7, 68-75.
71. Huang, Y. C., Wu, Y. R., Tseng, M. Y., Chen, Y. C., Hsieh, S. Y., & Chen, C. M. (2011). Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. PLoS One, 6, e15809.
72. Ishigami, N., Tokuda, T., Ikegawa, M., Komori, M., Kasai, T., Kondo, T., et al. (2012). Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. Movement Disorders, 27, 851-857.
73. Issaq, H. J., Veenstra, T. D., Conrads, T. P., & Felschow, D. (2002). The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochemical and Biophysical Research Communications, 292, 587-592.
74. Jahn, H., Wittke, S., Zurbig, P., Raedler, T. J., Arlt, S., Kellmann, M., et al. (2011). Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: Identification and prospective evaluation of new synaptic biomarkers. PLoS One, 6, e26540.
75. Joos, T. O., Schrenk, M., Hopfl, P., Kroger, K., Chowdhury, U., Stoll, D., et al. (2000). A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis, 21, 2641-2650.
76. Kawamata, T., Taniguchi, T., Mukai, H., Kitagawa, M., Hashimoto, T., Maeda, K., et al. (1998). A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. The Journal of Neuroscience, 18, 7402-7410.
77. Keeney, J. T., Swomley, A. M., Forster, S., Harris, J. L., Sultana, R., & Butterfield, D. A. (2013). Apolipoprotein A-I: Insights from redox proteomics for its role in neurodegeneration. Proteomics. Clinical Applications, 7, 109-122.
78. Kim,W.,Bennett, E. J.,Huttlin, E.L.,Guo,A.,Li, J.,Possemato,A., et al. (2011). Systematic and quantitative assessment of the ubiquitin-modified proteome. Molecular Cell, 44, 325-340.
79. Kislinger, T., & Emili, A. (2003). Going global: Protein expression profiling using shotgun mass spectrometry. Current Opinion in Molecular Therapeutics, 5, 285-293.
80. Kolch, W.,Pitt, A. (2010). Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nature Reviews. Cancer, 10, 618-629.
81. Koller, A., Washburn, M. P., Lange, B. M., Andon, N. L., Deciu, C., Haynes, P. A., et al. (2002). Proteomic survey of metabolic pathways in rice. Proceedings of the National Academy of Sciences of the United States of America, 99, 11969-11974.
82. Kumari, U., & Tan, E. K. (2009). LRRK2 in Parkinson's disease: Genetic and clinical studies from patients. The FEBS Journal, 276, 6455-6463.
83. Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., et al. (2001). The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Abeta1- 42. Journal of Neurochemistry, 78, 413-416.
84. Lehnert, S., Jesse, S., Rist, W., Steinacker, P., Soininen, H., Herukka, S.-K., et al. (2012). iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Experimental Neurology, 234, 499-505.
85. Le Roch, K. G., Johnson, J. R., Florens, L., Zhou, Y., Santrosyan, A., Grainger, M., et al. (2004). Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Research, 14, 2308-2318.
86. Lessner, G., Schmitt, O., Haas, S. J., Mikkat, S., Kreutzer, M., Wree, A., et al. (2010). Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. Journal of Proteome Research, 9, 4671-4687.
87. Leverenz, J. B., Umar, I., Wang, Q., Montine, T. J., McMillan, P. J., Tsuang, D. W., et al. (2007). Proteomic identification of novel proteins in corticalLewy bodies. Brain Pathology, 17, 139-145.
88. Li, Y. H., Wang, J., Zheng, X. L., Zhang, Y. L., Li, X., Yu, S., et al. (2011). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in Parkinson's disease. European Neurology, 65, 105-111.
89. Li, X., Zhang, Y., Hu, Y., Chang, M., Liu, T., Wang, D., et al. (2008). Chaperone proteins identified from synthetic proteasome inhibitor-induced inclusions in PC12 cells by proteomic analysis. Acta Biochimica et Biophysica Sinica, 40, 406-418.
90. Licker, V., Cote, M., Lobrinus, J. A., Rodrigo, N., Kovari, E., Hochstrasser, D. F., et al. (2012). Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease. Journal of Proteomics, 75, 4656-4667.
91. Lim, Y. A., Rhein, V., Baysang, G., Meier, F., Poljak, A., Raftery, M. J., et al. (2010). Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics, 10, 1621-1633.
92. Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787-795.
93. Lin, X., Cook, T. J., Zabetian, C. P., Leverenz, J. B., Peskind, E. R., Hu, S. C., et al. (2012). DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Scientific Reports, 2, 954.
94. Lopez, M. F., & Melov, S. (2002). Applied proteomics: Mitochondrial proteins and effect on function. Circulation Research, 90, 380-389.
95. Maccioni, R. B., Farias, G., Morales, I., & Navarrete, L. (2010). The revitalized tau hypothesis on Alzheimer's disease. Archives of Medical Research, 41, 226-231.
96. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298, 1912-1934.
97. Marras, C., & Lang, A. (2013). Parkinson's disease subtypes: Lost in translation? Journal of Neurology, Neurosurgery, and Psychiatry, 84, 409-415.
98. Martin, Z. S., Neugebauer, V., Dineley, K. T., Kayed, R., Zhang, W., Reese, L. C., et al. (2012). alpha-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. Journal of Neurochemistry, 120, 440-452.
99. Matt, P., Fu, Z., Fu, Q., & Van Eyk, J. E. (2008). Biomarker discovery: Proteome fractionation and separation in biological samples. Physiological Genomics, 33, 12-17.
100. Migliore, L., & Coppede, F. (2002). Genetic and environmental factors in cancer and neurodegenerative diseases. Mutation Research, 512, 135-153.
101. Mitsui, K., Doi, H., & Nukina, N. (2006). Proteomics of polyglutamine aggregates. Methods in Enzymology, 412, 63-76.
102. Mudher, A., & Lovestone, S. (2002). Alzheimer's disease-Do tauists and baptists finally shake hands? Trends in Neurosciences, 25, 22-26.
103. Nilsson, A., Falth, M., Zhang, X., Kultima, K., Skold, K., Svenningsson, P., et al. (2009). Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease. Molecular & Cellular Proteomics, 8, 1094-1104.
104. Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., Steen, H., Pandey, A., et al. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular & Cellular Proteomics, 1, 376-386.
105. Pan, S., Rush, J., Peskind, E. R., Galasko, D., Chung, K., Quinn, J., et al. (2008). Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. Journal of Proteome Research, 7, 720-730.
106. Pankratz, N., & Foroud, T. (2007). Genetics of Parkinson disease. Genetics in Medicine, 9, 801-811.
107. Pardo, L. M., & van Duijn, C. M. (2005). In search of genes involved in neurodegenerative disorders. Mutation Research, 592, 89-101.
108. Pasinetti, G. M., Ungar, L. H., Lange, D. J., Yemul, S., Deng, H., Yuan, X., et al. (2006). Identification of potential CSF biomarkers in ALS. Neurology, 66, 1218-1222.
109. Peng, J., Schwartz, D., Elias, J. E., Thoreen, C. C., Cheng, D., Marsischky, G., et al. (2003). A proteomics approach to understanding protein ubiquitination. Nature Biotechnology, 21, 921-926.
110. Periquet, M., Corti, O., Jacquier, S., & Brice, A. (2005). Proteomic analysis of parkin knockout mice: Alterations in energy metabolism, protein handling and synaptic function. Journal of Neurochemistry, 95, 1259-1276.
111. Perluigi, M., Swomley, A. M., & Butterfield, D. A. (2014). Redox proteomics and the dynamic molecular landscape of the aging brain. Ageing Research Reviews, 13, 75-89.
112. Plum, S., Helling, S., Theiss, C., Leite, R. E., May, C., Jacob-Filho, W., et al. (2013). Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis. Journal of Proteomics, 94, 202-206.
113. Ranganathan, S., Williams, E., Ganchev, P., Gopalakrishnan, V., Lacomis, D., Urbinelli, L., et al. (2005). Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Journal of Neurochemistry, 95, 1461-1471.
114. Rhodes, S. L., Sinsheimer, J. S., Bordelon, Y., Bronstein, J. M., & Ritz, B. (2011). Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Annals of Human Genetics, 75, 195-200.
115. Riederer, I. M., Schiffrin, M., Kovari, E., Bouras, C., & Riederer, B. M. (2009). Ubiquitination and cysteine nitrosylation during aging and Alzheimer's disease. Brain Research Bulletin, 80, 233-241.
116. Rinalducci, S., Murgiano, L., & Zolla, L. (2008). Redox proteomics: Basic principles and future perspectives for the detection of protein oxidation in plants. Journal of Experimental Botany, 59, 3781-3801.
117. Ringman, J. M., Schulman, H., Becker, C., Jones, T., Bai, Y., Immermann, F., et al. (2012). Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Archives of Neurology, 69, 96-104.
118. Rodolfo, C., Ciccosanti, F., Giacomo, G. D., Piacentini, M., & Fimia, G. M. (2010). Proteomic analysis of mitochondrial dysfunction in neurodegenerative diseases. Expert Review of Proteomics, 7, 519-542.
119. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., et al. (2004). Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Molecular & Cellular Proteomics, 3, 1154-1169.
120. Rudrabhatla, P., Grant, P., Jaffe, H., Strong, M. J., & Pant, H. C. (2010). Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ. FASEB Journal, 24, 4396-4407.
121. Saez-Valero, J., Barquero, M. S., Marcos, A., McLean, C. A., & Small, D. H. (2000). Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 69, 664-667.
122. Savino, R., Paduano, S., Preiano, M., & Terracciano, R. (2012). The proteomics big challenge for biomarkers and new drug-targets discovery. International Journal of Molecular Sciences, 13, 13926-13948.
123. Schirmer, E. C., Florens, L., Guan, T., Yates, J. R., 3rd., & Gerace, L. (2003). Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science, 301, 1380-1382.
124. Schonberger, S. J., Edgar, P. F., Kydd, R., Faull, R. L., & Cooper, G. J. (2001). Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. Proteomics, 1, 1519-1528.
125. Sebolt-Leopold, J. S., & Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews. Cancer, 4, 937-947.
126. Shiozaki, A., Tsuji, T., Kohno, R., Kawamata, J., Uemura, K., Teraoka, H., et al. (2004). Proteome analysis of brain proteins in Alzheimer's disease: Subproteomics following sequentially extracted protein preparation. Journal of Alzheimer's Disease, 6, 257-268.
127. Shirasaki, D. I., Greiner, E. R., Al-Ramahi, I., Gray, M., Boontheung, P., Geschwind, D. H., et al. (2012). Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron, 75, 41-57.
128. Sin, N., Meng, L., Auth, H., & Crews, C. M. (1998). Eponemycin analogues: Syntheses and use as probes of angiogenesis. Bioorganic & Medicinal Chemistry, 6, 1209-1217.
129. Sinha, A., Srivastava, N., Singh, S., Singh, A. K., Bhushan, S., Shukla, R., et al. (2009). Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: A proteomic approach. Clinica Chimica Acta, 400, 14-20.
130. Smith, D. J. (2009). Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics. Journal of Bioenergetics and Biomembranes, 41, 487-491.
131. Stasyk, T., Morandell, S., Bakry, R., Feuerstein, I., Huck, C. W., Stecher, G., et al. (2005). Quantitative detection of phosphoproteins by combination of two-dimensional difference gel electrophoresis and phosphospecific fluorescent staining. Electrophoresis, 26, 2850-2854.
132. Staunton, L., Zweyer, M., Swandulla, D., & Ohlendieck, K. (2012). Mass spectrometrybased proteomic analysis of middle-aged vs. aged vastus lateralis reveals increased levels of carbonic anhydrase isoform 3 in senescent human skeletal muscle. International Journal of Molecular Medicine, 30, 723-733.
133. Steinberg, T. H., Agnew, B. J., Gee, K. R., Leung, W. Y., Goodman, T., Schulenberg, B., et al. (2003). Global quantitative phosphoprotein analysis using multiplexed proteomics technology. Proteomics, 3, 1128-1144.
134. Suchkov, S. V., Gnatenko, D. A., Kostiushev, D. S., Krynskii, S. A., & Pal'tsev, M. A. (2013). Proteomics as a fundamental tool for subclinical screening, tests verification and assessment of applied therapy. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 1, 65-71.
135. Sui, X., Ren, X., Huang, P., Li, S., Ma, Q., Ying, M., et al. (2014). Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: Implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease. Journal of Alzheimer's Disease, 40, 575-586.
136. Suszynska-Zajczyk, J., Luczak, M., Marczak, L., & Jakubowski, H. (2014). Hyperhomocysteinemia and bleomycin hydrolase modulate the expression of mouse brain proteins involved in neurodegeneration. Journal of Alzheimer's Disease, 40, 713-726.
137. Sutinen, E. M., Pirttila, T., Anderson, G., Salminen, A., & Ojala, J. O. (2012). Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. Journal of Neuroinflammation, 9, 199.
138. Takano, M., Yamashita, T., Nagano, K., Otani, M., Maekura, K., Kamada, H., et al. (2013). Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using twodimensional fluorescence difference in gel electrophoresis. Neuroscience Letters, 534, 85-89.
139. Tandan, R., & Bradley, W. G. (1985a). Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Annals of Neurology, 18, 271-280.
140. Tandan, R., & Bradley, W. G. (1985b). Amyotrophic lateral sclerosis: Part 2. Etiopathogenesis. Annals of Neurology, 18, 419-431.
141. Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002). Toxic proteins in neurodegenerative disease. Science, 296, 1991-1995.
142. Thompson, A., Schafer, J. R., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G. N., et al. (2003). Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Analytical Chemistry, 75, 1895-1904.
143. Tsuang, D. W., & Bird, T. D. (2002). Genetics of dementia. The Medical Clinics of North America, 86, 591-614.
144. Turk, B. (2006). Targeting proteases: Successes, failures and future prospects. Nature Reviews. Drug Discovery, 5, 785-799.
145. Tyers, M., & Mann, M. (2003). From genomics to proteomics. Nature, 422, 193-197.
146. Ünlü, M., Morgan, M. E., Minden, J. S. (1997). Difference gel electrophoresis. A single gel method for detecting changes in protein extracts. Electrophoresis, 18, 2071-2077.
147. Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
148. Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., et al. (2001). Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. American Journal of Human Genetics, 68, 895-900.
149. Varga, E., Glauner, T., Koppen, R., Mayer, K., Sulyok, M., Schuhmacher, R., et al. (2012). Stable isotope dilution assay for the accurate determination of mycotoxins in maize by UHPLC-MS/MS. Analytical and Bioanalytical Chemistry, 402, 2675-2686.
150. Vijitruth, R., Liu, M., Choi, D. Y., Nguyen, X. V., Hunter, R. L., & Bing, G. (2006). Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. Journal of Neuroinflammation, 3, 6.
151. Villen, J., & Gygi, S. P. (2008). The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nature Protocols, 3, 1630-1638.
152. Villeneuve, L., Tiede, L. M., Morsey, B., & Fox, H. S. (2013). Quantitative proteomics reveals oxygen-dependent changes in neuronal mitochondria affecting function and sensitivity to rotenone. Journal of Proteome Research, 12, 4599-4606.
153. Washburn, M. P., Wolters, D., & Yates, J. R., 3rd. (2001). Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nature Biotechnology, 19, 242-247.
154. Westphal, C. H., & Chandra, S. S. (2013). Monomeric synucleins generate membrane curvature. The Journal of Biological Chemistry, 288, 1829-1840.
155. Wijesekera, L. C., & Leigh, P. N. (2009). Amyotrophic lateral sclerosis. Orphanet Journal of Rare Diseases, 4, 3.
156. Wijte, D., McDonnell, L. A., Balog, C. I., Bossers, K., Deelder, A. M., Swaab, D. F., et al. (2012). A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. Methods, 56, 500-507.
157. Wilkins, M. R., Pasquali, C., Appel, R. D., Ou, K., Golaz, O., Sanchez, J. C., et al. (1996). From proteins to proteomes: Large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY), 14, 61-65.
158. Williams, S. F., & Smallridge, R. C. (2004). Targeting the ERK pathway: Novel therapeutics for thyroid cancer. Current Drug Targets. Immune, Endocrine and Metabolic Disorders, 4, 199-220.
159. Wu, C. C., & MacCoss, M. J. (2002). Shotgun proteomics: Tools for the analysis of complex biological systems. Current Opinion in Molecular Therapeutics, 4, 242-250.
160. Xia, Q., Liao, L., Cheng, D., Duong, D. M., Gearing, M., Lah, J. J., et al. (2008). Proteomic identification of novel proteins associated with Lewy bodies. Frontiers in Bioscience, 13, 3850-3856.
161. Xun, Z., Sowell, R. A., Kaufman, T. C., & Clemmer, D. E. (2008). Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease. Molecular & Cellular Proteomics, 7, 1191-1203.
162. Yang, H., Wittnam, J. L., Zubarev, R. A., & Bayer, T. A. (2013). Shotgun brain proteomics reveals early molecular signature in presymptomatic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 37, 297-308.
163. Yates, J. R., Ruse, C. I., & Nakorchevsky, A. (2009). Proteomics by mass spectrometry: Approaches, advances, and applications. Annual Review of Biomedical Engineering, 11, 49-79.
164. Ye, Y., & Rape, M. (2009). Building ubiquitin chains: E2 enzymes at work. Nature Reviews. Molecular Cell Biology, 10, 755-764.
165. Yu, C., & Cohen, L. (2004). Tissue sample preparation-Not the same old grind. LC-GC Europe, 17, 96-111.
166. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., et al. (1995). Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Research, 55, 3752-3756.
167. Zabel, C., & Klose, J. (2004). Influence of Huntington's disease on the human and mouse proteome. International Review of Neurobiology, 61, 241-283.
168. Zabel, C., Mao, L., Woodman, B., Rohe, M., Wacker, M. A., Klare, Y., et al. (2009). A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Molecular & Cellular Proteomics, 8, 720-734.
169. Zahid, S., Oellerich, M., Asif, A. R., & Ahmed, N. (2012). Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer's disease patients. Journal of Neurochemistry, 121, 954-963.
170. Zareba-Koziol, M., Szwajda, A., Dadlez, M., Wyslouch-Cieszynska, A., & Lalowski, M. (2014). Global analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain-clues for synaptic pathology. Molecular & Cellular Proteomics, 13, 2288-2305.
171. Zhang, X., Zhou, J. Y., Chin, M. H., Schepmoes, A. A., Petyuk, V. A., Weitz, K. K., et al. (2010). Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model. Journal of Proteome Research, 9, 1496-1509.
172. Zhao, X., Xiao, W. Z., Pu, X. P., & Zhong, L. J. (2010). Proteome analysis of the sera from Chinese Parkinson's disease patients. Neuroscience Letters, 479, 175-179.
173. Zhou, J. Y., Afjehi-Sadat, L., Asress, S., Duong, D. M., Cudkowicz, M., Glass, J. D., et al. (2010). Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: Discovery by a proteomics approach. Journal of Proteome Research, 9, 5133-5141.
174. Zieske, L. R. (2006). A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. Journal of Experimental Botany, 57, 1501-1508.
175. Zilkova, M., Koson, P., & Zilka, N. (2006). The hunt for dying neurons: Insight into the neuronal loss in Alzheimer's disease. Bratislavské Lekárske Listy, 107, 366-373.